These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 25430444)
1. Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining. Ma D; Yang B; Zhou Z; Pan D; Zhang X Chin Med J (Engl); 2014; 127(23):4031-5. PubMed ID: 25430444 [TBL] [Abstract][Full Text] [Related]
2. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391 [TBL] [Abstract][Full Text] [Related]
3. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade. Gyftopoulos K; Vourda K; Sakellaropoulos G; Perimenis P; Athanasopoulos A; Papadaki E Urol Int; 2011; 87(4):464-9. PubMed ID: 21912077 [TBL] [Abstract][Full Text] [Related]
4. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635 [TBL] [Abstract][Full Text] [Related]
5. [Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications]. Gao WJ; Wang YM; Wang CH; Yang XK; Wan L; Li WP Zhonghua Nan Ke Xue; 2013 Apr; 19(4):315-20. PubMed ID: 23678709 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV. Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611 [TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma]. Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337 [TBL] [Abstract][Full Text] [Related]
8. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia. Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460 [TBL] [Abstract][Full Text] [Related]
9. Impact of primary hypertension on hematuria of the patients with benign prostatic hyperplasia. Guo LJ; Tang Y; Guo CM; Zhang XH Chin Med J (Engl); 2010 May; 123(9):1154-7. PubMed ID: 20529555 [TBL] [Abstract][Full Text] [Related]
10. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768 [TBL] [Abstract][Full Text] [Related]
11. [Correlation of histological prostatitis with PSA, prostate volume, PSAD, IPSS, Qmax and PVR in BPH patients]. Zhang HT; Xu Y; Chang JW; Zhang ZH; Liu RL; Ma BJ Zhonghua Nan Ke Xue; 2012 Mar; 18(3):208-11. PubMed ID: 22474983 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. Jackson MW; Bentel JM; Tilley WD J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664 [TBL] [Abstract][Full Text] [Related]
14. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia]. Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595 [TBL] [Abstract][Full Text] [Related]
15. [Histological changes of the prostate and acute urinary retention in patients with benign prostatic hyperplasia]. Bao QB; He GH; Liu GY; Zhang CG; Yang C Zhonghua Nan Ke Xue; 2013 Sep; 19(9):811-4. PubMed ID: 24386860 [TBL] [Abstract][Full Text] [Related]
16. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Sakamoto S; Yokoyama M; Zhang X; Prakash K; Nagao K; Hatanaka T; Getzenberg RH; Kakehi Y Endocrinology; 2004 Jun; 145(6):2929-40. PubMed ID: 14988385 [TBL] [Abstract][Full Text] [Related]
17. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Soulitzis N; Karyotis I; Delakas D; Spandidos DA Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871 [TBL] [Abstract][Full Text] [Related]
18. [Histological characteristics of the prostate in men who receive re-TURP for benign prostatic hyperplasia and their clinical significance]. Sun QZ; Guan TY; Qi JG; Cao JY; Wu G; Yang N; Cheng ZY; Liang J; Wang Q Zhonghua Nan Ke Xue; 2010 Feb; 16(2):118-22. PubMed ID: 20369693 [TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. Ravindranath N; Wion D; Brachet P; Djakiew D J Androl; 2001; 22(3):432-43. PubMed ID: 11330643 [TBL] [Abstract][Full Text] [Related]
20. [Correlation of benign prostatic hyperplasia with hyperlipemia]. Li PJ; Zhang XH; Guo LJ; Na YQ Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]